Innovative Heart-Specified Stem Cell Therapy Opens a New Chapter in Cardiovascular Regenerative Medicine

Mont-Saint-Guibert, Belgium, May 16, 2011 – The Belgian biotechnology company, Cardio3 BioSciences, a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, will present Phase II clinical trial data of the flagship product C3BS-CQR-1 (C-Cure®), at the EuroPCR Meeting in Paris on Wednesday, 18th May. This is the First-in-man use of lineage specified stem cells for the treatment of heart failure.

On behalf of the C-Cure international program, data will be presented by Dr. Dariouch Dolatabadi, Civil Hospital, Charleroi, Belgium and Investigator of the C3BS-CQR-1 (C-Cure) trial.

The trial demonstrates that heart failure patients improved heart function and exercise capacity at 6 months following treatment of C-Cure, an innovative stem cell therapy based on the Company’s “Cardiopoiesis” proprietary technology. Moreover, feasibility and safety of the C-Cure treatment regimen were established.

Data strongly suggest that C-Cure is a promising treatment for heart failure, one of the world’s greatest unmet medical needs. A person living to the age of 40 has a one-in-five risk of developing heart failure and, once the disorder is apparent, a one-in-three chances of dying within a year of diagnosis. 

More detailed information on

Download press release(s)

Communiqué de presse

76.51 Ko

Press release

76.51 Ko

Cardio3 BioSciences and ATMI, Inc. Sign a Letter of Intent

Next News

Cardio3 BioSciences and ATMI, Inc. Sign a Letter of Intent